Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Havn Life Sciences Inc. (HAVN.CN)

Havn Life Sciences Inc. (HAVN.CN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [CNSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [CNSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 59,358
  • Shares Outstanding, K 89,936
  • Annual Sales, $ 0 K
  • Annual Income, $ 0 K
  • 60-Month Beta N/A
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade HAVN.CN with:
  • Price/Earnings ttm N/A
  • Earnings Per Share ttm N/A
  • Most Recent Earnings -0.17 on 01/31/21
  • Next Earnings Date N/A
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

    TSX Biotechnology

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.640 +3.13%
on 06/17/21
0.790 -16.46%
on 05/19/21
-0.120 (-15.38%)
since 05/18/21
3-Month
0.600 +10.00%
on 04/05/21
0.800 -17.50%
on 05/17/21
-0.090 (-12.00%)
since 03/18/21

Most Recent Stories

More News
HAVN Life Announces Retail Partnership with Grocer, Choices Markets

Newly-launched line of natural health products to be available at all locations later this month

HAVN.CN : 0.660 (unch)
HAVLF : 0.5273 (+0.15%)
HAVN Life Launches New Line of Natural Health Products

Seven New Formulations That Support Brain Health and Immune Function Will Be Available Online and at Select Retail Locations Starting June 3

HAVN.CN : 0.660 (unch)
HAVLF : 0.5273 (+0.15%)
HAVN Life Completes Acquisition of Clinical Stage IP for Development of Cluster Headache Drug

The Company will seek Orphan Drug Designation to significantly reduce time to market

HAVN.CN : 0.660 (unch)
HAVLF : 0.5273 (+0.15%)
NIH Director Touted Benefits of Psychedelics Including Psilocybin and MDMA

Psychedelics may be one step closer to decriminalization. All after the Director of the National ...

CLXPF : 1.7100 (-1.72%)
MNMD : 3.74 (-1.32%)
HAVN.CN : 0.660 (unch)
HAVLF : 0.5273 (+0.15%)
MYCOF : 0.2300 (-2.04%)
NMDBF : 0.1310 (-7.75%)
MYCO.CN : 0.285 (-1.72%)
NEON.CN : 0.160 (-8.57%)
Lobe Sciences Secures Production and Supply Agreement for Vitamind Consumer Packaged Goods Products

Vancouver, British Columbia--(Newsfile Corp. - May 19, 2021) - Lobe Sciences Ltd. (CSE: LOBE) (OTC Pink: GTSIF) ("" or the "") is pleased to announce it has entered into a production and supply agreement...

LOBE.CN : 0.100 (-4.76%)
GTSIF : 0.0806 (-9.64%)
HAVN.CN : 0.660 (unch)
HAVLF : 0.5273 (+0.15%)
HAVN Life Secures Production & Supply Agreement to Expand Retail Product Offerings

Natural Health Products Will Be Manufactured and Packaged at the Company's New Facility

HAVN.CN : 0.660 (unch)
HAVLF : 0.5273 (+0.15%)
HAVN Life Enters into Agreement to Acquire Clinical Stage IP for Development of LSD-Derived API for Cluster Headaches

HAVN Life works towards substantiating a patent application and preclinical work

HAVN.CN : 0.660 (unch)
HAVLF : 0.5273 (+0.15%)
Havn Life CEO Tim Moore to Appear at Upcoming Q2 Investor SummitHavn Life CEO Tim Moore to Appear at Upcoming Q2 Investor Summit

Havn Life will join 80+ other small cap and micro-cap companies at leading event for investors

HAVN.CN : 0.660 (unch)
HAVLF : 0.5273 (+0.15%)
Havn Life Signs Exclusive Supply Agreement with ATMA Journey Centers

Havn Life to supply naturally-derived psilocybin to ATMA Journey Centers in Alberta and Nicoya Peninsula, Costa Rica

HAVN.CN : 0.660 (unch)
HAVLF : 0.5273 (+0.15%)
Havn Life Develops New Method for Rapid Psilocybin Testing

Havn Life has completed its analytical work under its Health Canada Section 56 exemption

HAVN.CN : 0.660 (unch)
HAVLF : 0.5273 (+0.15%)

Key Turning Points

3rd Resistance Point 0.690
2nd Resistance Point 0.680
1st Resistance Point 0.670
Last Price 0.660
1st Support Level 0.650
2nd Support Level 0.640
3rd Support Level 0.630

See More

Last Price 0.660
52-Week High N/A
Fibonacci 61.8% 1.130
Fibonacci 50% 1.010
Fibonacci 38.2% 0.890
52-Week Low N/A

See More

Business Summary

HAVN Life Sciences Inc is a biotechnology company engaged in the business of the research and development of psycho-pharmacological products, including the formulation of standardized psychoactive compounds derived from fungi. The products of the company will help to improve mental health and human performance....

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar